ArticleScience progress
The influence of cholesterol on the 5-year all-cause mortality of Parkinson patients with or without deep brain stimulation.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveParkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor and non-motor symptoms. While cholesterol metabolism has been implicated in PD pathogenesis, its role in long-term mortality remains unclear. The intention of this study was to evaluate if cholesterol parameters impact the 5-year all-cause mortality of PD patients.MethodsThis study has a retrospective cross-sectional design, including a total of 212 PD, patients which were grouped by treatment (DBS or BMT). Cognitive function, depressive symptoms, and motor status were assessed with standardized instruments. Cholesterol parameters (total cholesterol, LDL, HDL, TC/HDL ratio) were measured within ± 90 days of neuropsychological testing. Cox proportional hazards models and Kaplan-Meier analyses were used to examine associations with 5-year mortality.ResultsFive-year survival likelihood was 88.4% for DBS and 66.7% for BMT. However, cholesterol parameters emerged as non-significant predictors of mortality in the Cox regression model. Age occurred as the only significant predictor.ConclusionCholesterol levels do not appear to predict 5-year mortality in PD patients. Age was the strongest risk factor. Further studies are recommended to clarify cholesterol's role in PD progression and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.